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produces cross-sectional images that are 
composites of volume elements (NIH, 2006). 
The signal intensity for images especially 
in PET, corresponds to the concentration of 
radionuclide within the target tissue volume. 
PET is applied mainly in the clinical areas of 
cardiology, neurology and oncology, with the 
latter accounting for about 90% of all PET.
INTRODUCTION
Positron emission tomography (PET) is a rapidly developing imaging tool, with a clinical 
role that exceeds 15 years (Fathinul et al., 2013). It is a quantitative imaging technique that 
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ABSTRACT
Development of the positron emission tomography (PET) diagnostic radiopharmaceutical (18F)
fluoro-2-deoxy-D-glucose (18F-FDG) subsequently facilitated the discovery and clinical evaluation of 
several new tracers as imaging markers for cancer. While 18F-FDG is a widely employed marker for 
enhanced intracellular glycolysis and metabolic function, one of the newer tracers, (18F)-3’-fluoro-3’ 
deoxythymidine (18F-FLT), has been developed as a biomarker for cell proliferation. In this review, the 
potential of 18F-FLT as a biomarker for cancer imaging is discussed.
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The glucose derivative, (18F) fluorodeoxy glucose (18F-FDG), is the ubiquitous PET marker. 
However, there are numerous other tracers under development and with proven capability 
in highlighting a broad range of tissue metabolic functions. In a large meta-analysis, PET 
technique was found to change patients’ management to almost 30% (Gambhir et al., 2001). 
Though 18F-FDG is now widely used as a frontier in management of cancer patients, numerous 
studies have suggested that this marker is not universally selective for tumour imaging. This 
is because 18F-FDG is a glucose analogue and it is utilised by many cell types, which limits its 
specificity (Shields et al., 1998; Yun et al., 2003). 
To overcome this limitation, radioisotope-labelled thymidine derivatives have been 
developed to image cellular proliferation by PET. Radioisotope-labelled thymidine has a long 
history. Pyrimidine nucleoside was first labelled with radioisotope in 1969 by Langen and his 
collaborators. In their study, they described the radio-labelled form of pyrimidine nucleoside 
as a selective inhibitor of DNA synthesis. However, only in 1991, was fluorothymidine (FLT) 
labelled with 18F successfully introduced as carrier-added 18F-FLT (Wilson et al., 1991). Wilson 
and his collaborators monitored the efficacy of 3’-fluoro-3’-deoxy-thymidine (FDT) in HIV 
treatment. FDT is a fluorinated analogue of 3’-azido-thymidine (AZT), which was also found 
to be active against the HIV. However, FDT is more toxic than AZT (Wilson et al., 1991). 
Wilson and his collaborators successfully labelled the 3’-fluoro-3’-deoxy-thymidine (FDT) 
with the 18F to monitor the drug’s distribution and targeting in the body (Grierson et al., 1997). 
Development of the FLT marker was subsequently continued by Grierson et al. in 1997 
and it successfully introduced no-carrier-added 18F-FLT. The next year, 18F-FLT was first 
applied in imaging. The study was carried out to investigate animals and non-small cell lung 
cancer (NSCLC) patients (Shields et al., 1998). From that study, it was found that 18F-FLT was 
specifically taken up by tissues that actively proliferate, including bone marrow (Barthel et 
al., 2003). Although 18F-FLT appears to be a most promising marker, the major hurdle for its 
routine use is its low radiochemical yield during production. Nevertheless, it provides greater 
advantages to the clinicians in management of cancer patients. 
THE BASIS OF 18F-FLT AS A PROLIFERATION MARKER
The 18F-FLT marker is administered to the patient by intravenous injection. It is taken up in 
the cell via both passive diffusion and also by Na+-dependent carriers. The 18F-FLT marker, 
which is trapped in the cell, will undergo the phosphorylation process by thymidine kinase 
(TK1) and be converted into 18F-FLT-monophosphate (Been et al., 2004). Intracellular trapping 
and accumulation of 18F makes it possible to be detected by PET camera, which in turn gives 
a measure of the TK1 activity. 
In the physiological pathway, both thymidine and 18F-FLT encounter the same initial fate 
(Fig.1). Both of them will be phosphorylated by TK1 for DNA synthesis. However, for the 
18F-FLT marker, the DNA replication is inhibited due to the lack of the hydroxyl (-OH) group 
attached at the carbon number 3’-position on the sugar ring. Hence, the 18F-FLT marker will be 
trapped inside the proliferating cells, and its radioactive signature will continue to accumulate 
there.       
Potential of 3’-Fluoro-3’ Deoxythymidine
43Pertanika J. Sci. & Technol. 24 (1): 41 - 52 (2016)
The uptake of 18F-FLT by cells is correlated with TK1 activity (Barthel et al., 2003; Chen 
et al., 2005). TK1 activity in proliferating cells is noted to be 3 to 4 times higher in malignant 
cells compared to benign cells (Been et al., 2004). The enzymatic activity of TK1 reaches 
maximum level in the late G1 phase and S phase of the cell proliferative cycle. Therefore, 
monitoring of TK1 activity should give an early indication as to whether a cell population is 
in proliferative malignant state, or in benign state.  
POTENTIALS OF 18F-FLT IN ONCOLOGY
18F-FDG marker is known for its relative non-specificity. Hence, there are many active 
inflammatory diseases and some aggressive benign tumours that inevitably give high 18F-FDG 
uptake in cells. Furthermore, some disease processes healed by fibrosis leave a significant 
residual mass, thereby limiting categorisation of a complete response to 18F-FDG. 
In comparison, the FLT marker has the ability to demonstrate an increased rate of cellular 
proliferation and is potentially helpful in the setting of therapeutic monitoring as it has less 
affinity to inflammatory conditions. 18F-FLT is potentially a more specific marker than 18F-FDG 
with a high positive predictive value for malignancy. 18F-FLT marker is also potentially useful 
in the evaluation of cerebral malignancy due to the lack of background cerebral uptake, unlike 
the high cerebral activity normally seen in 18F-FDG. 
In addition, there is good evidence that 18F-FLT uptake is closely correlated with cellular 
proliferation with correlation between the intensity of uptake in lung cancer as measured by 
SUV with proliferation indices such as Ki-67 staining in a resected specimen (Hofman et al., 
Fig.1: Uptake mechanism of thymidine and 18F-FLT.
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2012). The ability of 18F-FLT to identify tissue with a high proliferative rate has potential 
applications in the assessment of haemopoietic tissue and high grade disease transformation in 
haematological malignancy. The assessment of bone marrow reserve is important in considering 
patients for chemotherapy or radionuclide therapy, which is potentially myelotoxic. 18F-FLT 
has the ability to document the extent and distribution of haemopoietic tissue, including the 
presence of extramedullary haemopoiesis, which can guide subsequent treatment choice. There 
are occasions when bone marrow sampling does not provide a representative picture of the 
true haemopoietic status due to sampling error and heterogeneous distribution of haemopoietic 
tissue (Fig.2).  
Fig.2: A 55-year-old man with stage IV diffuse large B cell lymphoma with nodal and multifocal 
bony disease and the pre-treatment bone marrow biopsy from the right posterior ilium showing 
hypocellular marrow and aplasia, in the presence of normal peripheral blood counts. 18F-FLT PET/
CT was performed, which demonstrated absence of proliferative tissue in the right posterior ilium 
but fairly normal distribution of hyperproliferative bone marrow elsewhere with no evidence of 
extramedullary haemopoiesis in the spleen or elsewhere. The 18F-FLT PET/CT findings suggested 
that the initial bone marrow biopsy result was non-representative of his true bone marrow status and 
the patient went on to undergo systemic chemotherapy treatment without any myelotoxicity problem 
(Image courtesy of The Peter Mac Callum Centre).
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DIAGNOSIS EVALUATION: 18F-FLT VERSUS 18F-FDG 
Pancreatic Cancer
18F-FLT has been used in imaging pancreatic-cancer-specific cell lines, SW-979 and BxPc-3. 
The study was performed by Seitz et al. (2002) to prove that 18F-FLT has greater specificity than 
18F-FDG. In that study, the 18F-FLT uptake was 18.4% and 5.2%, respectively. In comparison, 
18F-FDG was also administered to the same cell lines. It was observed that the 18F-FDG 
uptake was only 0.6% and 0.3% for the corresponding cells. Evidence such as no increased 
18F-FLT uptake was observed in normal pancreatic lobules in comparison with large 18F-FDG 
uptake detected in normal pancreatic lobules confirmed that 18F-FLT has higher specificity for 
pancreatic cancer.  
The previous work by Seitz was supported by the Herrmann group’s findings in 2008. In the 
study consisting of 21 patients diagnosed with malignant pancreatic tumours, 15 patients had an 
increased 18F-FLT uptake. Herrmann and his colleagues were able to demonstrate that 18F-FLT 
was a specific marker for pancreatic cancer (Herrmann et al., 2008). They also suggested that 
18F-FLT may be used to differentiate pancreatic cancer from pancreatic pseudotumors that 
were subjected to arise from chronic pancreatitis (Herrmann et al., 2008). As any other studies, 
Herrmann acknowledged that although the 18F-FLT showed high specificity for pancreatic 
cancer, it turned out that the sensitivity was reduced for malignant lesions (Herrmann et al., 
2008). 
Contrary to the Seitz et al. (2002) and Herrmann et al. (2008) studies, initial evaluation of 
18F-FLT for primary pancreatic study led by Quon et al. (2007) demonstrated the opposite. In a 
pilot study consisting of five patients who were newly diagnosed with unresectable pancreatic 
Fig.3: Coronal MIP-PET images using 18F-FLT in the assessment of skeletal sarcoma before (left) and 
after treatment (right). The images show an increased 18F-FLT intensity in the left lateral chest wall 
(marked), which appears less proliferative after treatment (right). (Image courtesy of The Peter Mac 
Callum Centre).
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cancer, the visual interpretation of the primary site was assessed using 18F-FLT PET/CT and 
18F-FDG PET/CT. In 18F-FLT PET/CT, the primary lesion was detectable in only two of the five 
patients, while all five showed lesions in the 18F-FDG PET/CT imaging (Quon et al., 2007). 
Throughout the study, 18F-FLT showed poor lesion detectability and low levels of uptake in 
the primary tumour compared to 18F-FDG. Hence, it was suggested that the use of 18F-FLT was 
not promising for characterisation of pancreatic cancer and it offerred no benefit in monitoring 
therapy due to poor baseline scan (Quon et al., 2007).  
Pulmonary Nodes and Lung Cancer
In pulmonary nodes and lung cancer, one expected difficulty in differentiating malignant from 
benign solitary pulmonary nodes (Been et al., 2004). Although 18F-FDG has proved to be a 
helpful and accurate diagnostic tool, with excellent sensitivity of 96.8% and good specificity of 
77.8%, reports of false-positives still originate, mainly from granulomatous and inflammatory 
disease. Thus, a more specific tracer that does not show uptake in inflammatory tissues would 
be useful. In the non-small cell lung cancer (NSCLC) patient, image with low background 
activity was acquired with the administration of 18F-FLT on patients (Been et al., 2004). Buck 
et al. (2003) further investigated 30 patients diagnosed with solitary pulmonary nodes (SPN) 
and deployed 18F-FLT as a marker. They reported 86% 18F-FLT uptake by the malignant 
lesions, whereas no 18F-FLT uptake was observed in benign lesions. This demonstrated that in 
distinguishing the malignant SPN, 18F-FLT had higher specificity than 18F-FDG.
Breast Cancer
On the contrary, in breast cancer cases, although multiple studies have been carried out by 
many groups using 18F-FLT, the results have not been consistent. In an early investigation in 
patients diagnosed with breast cancer, it was observed that 18F-FLT was taken up in breast 
cancer cells (Been et al., 2004). In another study by Silverman and his colleagues in 2002, there 
was a 1.3 to 2.3 times higher 18F-FLT uptake reported in primary breast cancers as compared 
to 18F-FDG uptake. However, in 2004, Smyczek-Gargya and his colleagues, investigated 12 
patients with breast cancer with 18F-FLT and compared it to 18F-FDG, concluding that 18F-FDG 
uptake was higher than 18F-FLT. Scientists agree that it is still unclear what will be the role 
for 18F-FLT in patients with breast cancer as inconsistent findings from multiple studies have 
led to uncertainty in the role of 18F-FLT in breast cancer management. Interestingly, the study 
of Been and his colleagues showed that 18F-FLT uptake predicted tumour marker response to 
chemotherapy better than 18F-FDG (Been et al., 2004). The latter work was supported by Pio 
and his colleagues in 2006 and also Kenny et al. (2007). Pio and his colleagues had evaluated 
the treatment response with 18F-FLT PET in patients diagnosed with breast cancer over 18F-FDG 
PET. Scans were done prior to chemotherapy treatment or anti-hormonal therapy two weeks 
after completion of the first treatment cycle and after the end of treatment or over a year if 
the treatment had not yet been completed. In the study, they found that changes in levels of 
the serum marker, CA27.29, were more strongly correlated with tumour 18F-FLT uptake than 
with 18F-FDG (Pio et al., 2006). Meanwhile, Kenny and his colleagues reported a significant 
association between tumour 18F-FLT uptakes with the Ki-67 labelling index (Kenny et al., 
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2007). Hence, it was proposed that measuring the early response to chemotherapy for locally 
advanced breast cancer is probably the most interesting research question for 18F-FLT studies 
in patients with breast cancer (Been et al., 2004; Pio et al., 2006; Kumar, 2007; Kenny et al., 
2007).       
Brain Cancer
In the management of brain tumours, PET provides information on the tumour grade and also 
assists in assessing the optimal site for biopsy. Several PET radiopharmaceutical markers have 
been used for brain cancer imaging. These include 18F-FDG, 18F-FLT, and 11C-Met (L-methyl-
[11C] methionine). Chen and his colleagues systematically compared 18F-FLT with 18F-FDG 
in human gliomas, in relation to sensitivity, in the evaluation of recurrent high-grade glioma 
(Chen et al., 2005). They discovered that uptake of 18F-FLT in glioma was relatively rapid. 
18F-FLT typically showed a similar uptake as for 18F-FDG. However, an interesting finding was 
that the 18F-FLT background uptake in normal brain tissue was low, and this could be due to a 
slow proliferation rate. This feature significantly showed that 18F-FLT has potential to derive 
a better mean standardised uptake value (SUV) in PET imaging of a tumour, as compared 
with 18F-FDG.
Although 18F-FDG has been used extensively in brain tumour imaging, one of the several 
major drawbacks of 18F-FDG in this context is its difficulty in characterising tumours in the 
brain. This is due to the high basal glucose metabolic rate of normal brain tissue. 18F-FDG uptake 
of low-grade tumours is generally similar to that of normal white matter, whereas high-grade 
tumour uptake can be similar to that of normal grey matter, resulting in limited sensitivity of 
lesion detection. In addition, in recurrent tumours the 18F-FDG uptake could be lower than the 
normal white matter, whereas in necrotic cells the 18F-FDG uptake could be higher than the 
normal white matter. It can be assumed that 18F-FLT has a theoretical advantage in detecting 
tumour recurrence as there is little uptake in normal brain. It has been agreed that 18F-FLT 
may help to define tumour activity by imaging tumours with greater sensitivity than 18F-FDG 
(Nitzsche et al., 2003). Another significant finding arose from a study by Nitzsche and his 
colleagues in 2003, who determined that 18F-FLT was greater to 18F-FDG for the detection of 
recurrent brain tumours after brachytherapy.   
A study by Dohmen and colleagues in 2000 compared the use of 18F-FLT with L-methyl-
11C-methionine (11C-MET) for the detection of brain tumours. They discovered that 18F-FLT 
showed higher tumour contrast compared to 11C-MET. However, low-grade brain tumours limit 
the application of 18F-FLT in brain tumour imaging as it showed poor visual distinction in that 
case (Been et al., 2004). Garlip (2003) discovered that the 18F-FLT standardised uptake value 
was higher than that of 11C-MET. Even though 18F-FLT has shown some advantages compared 
with 18F-FDG and 11C-MET, relatively small and therefore inconclusive studies have been 
published. There is a need to provide anatomical information and to further determine whether 
18F-FLT is able to differentiate between benign and malignant tissues and between residual 
tumour and radionecrosis. If 18F-FLT proves to be a sensitive and specific marker for the brain, 
it will be very useful for the next stages in management; namely establishing the best site for 
tumour biopsy and for planning of radiotherapy in heterogeneous tumour (Been et al., 2004). 
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Colorectal Cancer (CRC)
Francis and his colleagues in 2003 successfully imaged colorectal cancer using both 18F-FDG 
and 18F-FLT. Both markers displayed 100% sensitivity when imaging primary colorectal cancer. 
For visualisation of extra hepatic lesions, 18F-FDG and 18F-FLT demonstrated sensitivities of 
100% and 92% respectively (Francis et al., 2003). 
However, his study also demonstrated an increased uptake of 18F-FDG from non-malignant 
inflammatory peritoneal lesions, which were thus presumed to be malignant. This would 
lead to false-positive scans when using 18F-FDG. In contrast, such lesions showed no avidity 
for 18F-FLT, demonstrating a specificity that may be useful for further characterisation of 
equivocal lesions (Francis et al., 2003). His study concluded that in colorectal cancer, 18F-FLT 
demonstrated lower cellular trapping compared to 18F-FDG. The poor sensitivity displayed by 
18F-FLT makes it a poor candidate as a diagnostic tool for colorectal cancer. Although it lacks 
in sensitivity (inclusion of free positives), 18F-FLT has the potential to improve the specificity 
(rejection of false positives) for the detection of colorectal cancer.   
Another study led by Wang et al. (2009) investigated whether the use of dual-tracers, 
18F-FDG and 18F-FLT, could predict the biologic character of metastases in colorectal cancer. 
Wang et al. (2009) used animal modelling to prove that higher uptake of 18F-FLT could be 
correlated to a higher incidence of metastasis. The human colorectal cancer cell lines SW480 
and SW620 were generated in 20 mice, whereby the former was generated in the left front 
leg and latter was generated in the right front leg. Wang observed high uptake of 18F-FLT in 
mice from small animal PET/CT which correlated well with the overexpression of HSP27 and 
integrin ß3 in the left front leg of the mice (SW480) (Wang et al., 2009). On the other hand, 
high uptake of 18F-FDG was observed in the right front leg, which had been generated with 
SW620 cell lines but not by 18F-FLT. The overexpression of HSP27 and integrin ß3 in SW480, 
which observed higher uptake of 18F-FLT, was believed to reflect a higher rate of metastasis to 
lung and liver (Wang et al., 2009). Meanwhile, high uptake of 18F-FDG in SW620 cell lines can 
possibly correlate with lymphatic metastases (Wang et al., 2009). From the study, Wang and 
his colleagues (2009) suggested that a combination of the dual-tracers 18F-FLT and 18F-FDG 
could be used to predict the biologic behaviour of colorectal cancer.             
Lymphoma
Lymphoma is a type of malignancy that originates in lymphocytes of the immune system; 
particularly in lymph nodes and presenting as an enlargement of these nodes. For high-grade 
lymphoma visualisation, there is no dispute that 18F-FDG has been proven to be a sensitive 
method. However, for the low-grade (indolent) lymphoma, the value of 18F-FDG is still unclear 
(Been et al., 2004). Hence, 18F-FLT could in theory have an additional value as a tracer of 
proliferative tissues. Been (2004) also compared 18F-FLT and 18F-FDG in lymphoma patients. 
It was found that the mean standardised uptake value (SUV) for 18F-FLT was 4.5 whereas the 
mean SUV for 18F-FDG was 5. This showed that 18F-FDG had higher uptake in lymphoma. In 
terms of sensitivity, both markers were found to be comparable. As 18F-FLT uptake in lymphoma 
is closely correlated with the rate of proliferation, problems may arise during the prognosis 
in lymphoma. In the case of prognosis in lymphoma, the rate of proliferation is not always 
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correlated with lymphoma’s prediction (Been et al., 2004). In haematopoietic dysfunction cases, 
the 18F-FLT marker is able to determine the activity, extent and distribution of bone marrow 
reserve and hence, assist in decision making for a variety of clinical indications. 18F-FLT 
findings complement results of bone marrow aspiration and trephine biopsy (BMAT) and could 
be a useful tool for assessing response to novel treatments in patients with myeloproliferative 
diseases (Hofman et al., 2012). 
Melanoma
Melanoma is a malignant tumour of pigment cells (melanocytes), which are found predominantly 
in skin but also in the bowel and eye. Cobben and colleagues in 2003 used 18F-FLT in imaging 
of melanoma to compare with 18F-FDG. They discovered that the specificity and sensitivity of 
18F-FLT in imaging of melanoma was 60% and 88%, respectively. In contrast, the specificity and 
sensitivity using 18F-FDG was 83% and 92%, respectively. This indicates that the specificity and 
sensitivity of 18F-FLT for melanoma are lower than those of 18F-FDG. It appears that 18F-FLT 
is not a preferential marker when it comes to detection of melanoma.     
LIMIT OF 18F-FLT AS A CELLULAR PROLIFERATION MARKER
The extent of the agreement on whether 18F-FLT shows a net benefit in cellular proliferation has 
been continuously debated. The dispute arises due to the nature of DNA synthesis mechanisms: 
the thymidine salvage pathway and de novo synthesis pathway. In thymidine salvage pathway, 
thymidine is transported across the cell membrane and phosphorylated by TK1 into thymidine 
monosphosphate (TMP) before it is further phosphorylated into thymidine diphosphate (TDP) 
and thymidine triphosphate (TTP) (McKinley et al., 2013). TTP then is incorporated into the 
DNA. 
In contrast to thymidine salvage, the de novo synthesis pathway uses deoxyuridine 
monophosphate as an alternative for conversion into TMP through the action of the thymidylate 
synthase (TS) enzyme. TPM is then further phosphorylated and incorporated into the DNA. 
Due to this nature of the DNA synthesis mechanism, it is assumed that previous studies using 
18F-FLT may underestimate cell proliferation in de novo pathway-dependent tumours. In 2013, 
McKinley and his colleagues conducted a study to demonstrate that 18F-FLT is poorly reflected 
as a proliferative index in some tumours that utilise the de novo pathway. They generated the 
human colorectal cancer cell lines, HCT-116 (parental line) and HCT-116p21 in the cell lines 
and also in the xenografts to explore the effect of p21 deletion on 18F-FLT. Interestingly, in 
HCT-116p21 cells, elevated levels of the TS enzyme was observed. Meanwhile, the level of 
TK1 diminished. When 18F-FLT PET was performed on the xenografts to demonstrate the 
sensitivity of 18F-FLT to de novo pathway utilisation, the HCT-116 xenografts manifested 
greater uptake than the analogous HCT-116p21 xenografts (McKinley et al., 2013). The 
finding were supported by the findings of a previous study led by Moroz et al. (2011) who 
suggested that 18F-FLT uptake was unrepresentative of xenografts growth in tumours utilising 
the de novo pathway. From the findings, McKinley et al. (2013) concluded that 18F-FLT PET 
cannot discriminate moderately proliferative, thymidine salvage-driven tumours from high-
proliferative index tumours that rely primarily upon the de novo pathway. 
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CONCLUSION
It is well accepted that 18F-FDG is the ubiquitous marker in PET oncological practice. 
Nevertheless, 18F-FLT is an exciting marker with improved specificity that could be the number 
one candidate for therapeutic monitoring. Thereby, future research should continue to probe 
the potential of 18F-FLT as a powerful marker for cellular proliferation. 
REFERENCES
Barthel, H., Cleij, M. C., Collingridge, D. R., Hutchinson, O. C., Osman, S., & He, Q. (2003). 3’-Deoxy-
3’[18F]Fluorothymidine as a new marker for monitoring tumour response to antiproliferative therapy 
in vivo with positron emission tomography. Cancer Research, 63, 3791-3798.
Been, L. B., Suurmeijer, A. J. H., Cobben, D. C. P., Jager, P. L., Hoekstra, H. J., & Elsinga, P. H. (2004). 
[18F]FLT-PET in oncology: current status and opportunities. European Journal of Nuclear Medicine 
and Molecular Imaging, 31(12), 1559-1672.
Buck, A. K., Halter, G., Schirrmeister, H., Kotzerke, J., Wurziger, I., & Glatting,  G. (2003). Imaging 
proliferation in lung tumours with PET: 18F-FLT versus 18F-FDG. Journal of Nuclear Medicine, 
44(9), 1426-1431.
Cancer Imaging Program. (2006). An investigational positron emission tomography (PET) 
radiopharmaceutical for injection and intended for use as an in vivo diagnostic for imaging active 
cellular proliferation of malignant tumours. Division of Cancer Treatment and Diagnosis (4th ed.). 
National Institute of Health.
Chen, W., Cloughesy, T., Kamdar, N., Satyamurthy, N., Bergsneider, M., & Liau, L. (2005). Imaging 
proliferation in brain tumours with 18F-FLT PET: Comparison with 18F-FDG. Journal of Nuclear 
Medicine, 46(6), 945-952.
Cobben, D. C. P., Jager, P. L., Elsinga, P. H., Maas, B., Suurmeijer, A. J. H., & Hoekstra,  H. J. (2003). 
3’-18Fluoro-3’-deoxy-L-thymidine: A new tracer for staging metastatic melanoma? Journal of Nuclear 
Medicine, 44, 1927-1932.
Dohmen, B. M., Shield, A. F., Grierson, J. R., Kuntzsch, M., Reimold, M., & Sloan, A. (2000). [18F]
FLT-PET in brain tumours. Journal of Nuclear Medicine, 41(supplementary), 216P. 
Fathinul, F., Nordin, A. J., & Lau, W. F. E. (2013). 18(F) FDG-PET/CT is a useful molecular marker 
in evaluating tumor aggressiveness; A revised understanding of an in-vivo FDG PET imaging that 
alludes the alteration of cancer biology. Cell Biochemistry and Biophysics, 66(1), 37-43.  
Francis, D. L., Visvikis, D., Costa, D. C., Arulampalam,  T. H. A., Townsend, C., & Luthra, S. K. (2003). 
Potential impact of [18F]3’-deoxy-3’-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron 
emission tomography for colorectal cancer. European Journal of Nuclear Medicine and Molecular 
Imaging, 30(7), 988-994.
Gambhir, S. S., Czermin, J., Shcwimmer, J., Silverman, D. H., Coleman, R. E., & Phelps, M. E. (2001). 
A tabulated summary of the FDG PET literature. Journal of nuclear medicine, 42(5 suppl), 1S-93S.
Garlip, G., Dittmar, C., Kracht, L., Thomas, A. V., Herholz, K., & Heiss, W. D. (2003). Identification 
of DNA and amino acid metabolism in human gliomas by PET. Journal of Nuclear Medicine, 44(5), 
167P-167P.
Potential of 3’-Fluoro-3’ Deoxythymidine
51Pertanika J. Sci. & Technol. 24 (1): 41 - 52 (2016)
Grierson, J. R., Shields, A. F., & Eary, J. F. (1997). Development of a radiosynthesis for 3’-[F-18] 
fluoro-3’-deoxynucleosides. Journal of Labelled Compounds and Radiopharmaceuticals, 40, 60-62.
Herrmann, K., Eckel, F., Schmidt, S., Schneidhauer, K., Krause, B. J., & Kleeff, J. (2008). In vivo 
characterization of proliferation for discriminating cancer from pancreatic pseudotumors. Journal of 
Nuclear Medicine, 49(9), 1437-1444.
Hofman, M., Segard, T., Khan, Z., Seymour, J., & Hicks, R. (2012). Clinical utility of 18F-fluoro-
L-thymidine (FLT) PET to evaluate bone marrow distribution and proliferation in patients with 
haematopoietic dysfunction. Journal of Nuclear Medicine, 53(S1), 538.
Kenny, L., Coombes, R. C., Vigushin, D. M., Al-Nahhas, A., Shousha, S., & Aboagye, E. O. (2007). 
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer 
patients with 3’-deoxy-3’-[18F]fluorothymidine positron emission tomography. European Journal of 
Nuclear Medicine and Molecular Imaging, 34(9), 1339-1347.
Kumar, R. (2007). Assessment of therapy response in malignant tumours with 18F-fluorothymidine. 
European Journal of Nuclear Medicine and Molecular Imaging, 34(9), 1334-1338.
Langen, P., Etzol, G., Hintsche, R., & Kowollik, G. (1969). 3’-deoxy-3’-fluorothymidine, a new selective 
inhibitor of DNA-synthesis. Acta biologica et medica Germanica, 23(6), 759-766.
McKinley, E. T., Ayers, G. D., Smith, R. A., Saleh, S. M., Zhao, P., Washington, M. K., Coffey, R. J., 
& Manning, H. C. (2013). Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. Plos 
One, 8(3), 1-9.
Moroz, M. A., Kochetkov, T., Cai, S., Wu, J., & Shamis, M. (2011). Imaging colon cancer response 
following treatment with AZD1152: A preclinical analysis of [18F]fluoro-2-deoxyglucose and 3’-deoxy-
3’[18F]fluorothymidine imaging. Clinical Cancer Research, 17(5), 1099-1110.
Nitzsche, E. U., Walter, M., Schirp, U., Machulla, H. J., & Mueller, J. (2003). Combined PET imaging 
of proliferation and glycolysis for follow up of brachytherapy in brain tumours. Society of Nuclear 
Medicine 50th Annual Meeting.
Pio, B. S., Park, C. K., Pietra, R., Hsueh, W. A., Satyamurthy, N., & Pegram, M. D. (2006). Usefulness 
of 3’-[F-18]Fluoro-3’-deoxythymidine with positron emission tomography in predicting breast cancer 
response to therapy. Molecular Imaging and Biology, 8(1), 36-42.
Quon, A., Chang, S. T., Chin, F., Kamaya, A., Dick, D. W., Loo, J. B. W., Gambhir, S. S., & Koong, A. 
C. (2008). Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic 
cancer. European Journal of Nuclear Medicine and Molecular Imaging, 35(3), 527-531.
Seitz, U., Wagner, M., Neumaier, B., Wawra, E., Glatting, G., & Leder, G. (2002). Evaluation of 
pyrimidine metabolising enzymes and in vitro uptake 3’-[18F]fluoro-3’-deoxythymidine [18F]FLT 
in pancreatic cancer lines. European Journal of Nuclear Medicine and Molecular Imaging, 29(9), 
1174-1181.
Shields, A. F., Grierson, J. R., Dohmen, B. M., Machulla, H. J., Stayanoff, J. C., & Lawhorn-Crews, J. 
M. (1998). Imaging proliferation in vivo with [18F]FLT and positron emission tomography. Nature 
Medicine, 4(11), 1334-1336.
Silverman, D. H., Pio, B. S., Satyamurthy, N., Park, C. K., Chap, L., & Pegram, M. (2002). Monitoring 
effects of breast cancer chemotherapy with fluorodeoxyglucose and fluoro-L-thymidine. Journal of 
Nuclear Medicine, 43(5), 311.
Hishar Hassan et al.
52 Pertanika J. Sci. & Technol. 24 (1): 41 - 52 (2016)
Smyczek- Gargya, B., Fersis, N., Dittmann, H., Vogel, U., Reischl, G., & Machulla, H. J. (2004). PET 
with [18F]fluorothymidine for imaging of primary breast cancer: A pilot study. European Journal of 
Nuclear Medicine and Molecular Imaging, 31(5), 720-724.
Wang, H., Jinming, Z., Jiahe, T., Baolin, Q., Tianran, L., Yingmao, C., Jian, L., & Shan, W. (2009). Using 
dual-tracer PET to predict the biologic behaviour of human colorectal cancer. Journal of Nuclear 
Medicine, 50(11), 1857-1864.
Wilson, I. K., Chatterjee, S., & Wolf, W. (1991). The use of 3’-fluoro-3’-deoxythymidine and studies 
of its 18F-labelling, as a tracer for the non-invasive monitoring of the biodistribution of drugs against 
AIDS. Journal of Fluorine Chemistry, 55, 283-289.
Yun, M., Oh, S. J., Ha, H. J., Ryu, J. S., & Moon, D. H. (2003). High radiochemical yield synthesis 
of 3’-deoxy-3’-[18F]fluorothymidine using (5’-O-dimethoxytrityl-2’-deoxy-3’-O-nosyl-β-D-threo 
pentofuranosyl)thymine and its 3-N-BOC-protected analogue as a labelling precursor. Nuclear 
Medicine and Biology, 30(2), 151-157.
